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ABSTRACT 
  
         Colorectal cancer is an important tumor of the GIT arising 
from the epithelial lining the inner surface of the colon& rectum& 
from the crypts of Liberkϋhn. 
        This is a retrospective study conducted on Sudanese patients 
during the period from January 2001 to December 2004 at Ibn 
Sina Hospital, Khartoum, Sudan. 
        The study aimed to determine the histopathological pattern of 
CRC, & to show the correlation between the histopathological type 
of the tumor& the age, sex, residency distribution, & clinical 
presentation.  comprised 100 patients, of which 56 were males& 
44 were females with a ratio of 1.1: 1 to each other. The age for all 
patients ranges between 14- 85 years. 
        In this study there was a high proportion of early onset tumor 
(33% of cases were < 40 years), & left sided subsite distribution of 
CRC (77% of cases were in the rectum, sigmoid colon, & recto- 
sigmoid junction). 
        Rectal bleeding represented the majority (76%) of the 
symptoms of CRC. The duration of symptoms varied from one to 
twelve months with the majority of patients (61.2%) having 
symptoms < 6 months. 
 V
        By reviewing the slides, only five histological types were 
identified. There were 74(74%) adenocarcinoma, 13(13%) 
mucinous adenocarcinoma, 7(7%) signet ring cell carcinoma, 
5(5%) papillary carcinoma, & one (1%) anaplastic carcinoma. 
        In conclusion, we share many epidemiological features of 
developing countries for CRC. These include left subsite 
distribution& early-onset CRC. We stress the significance of the 
public health education& national screening program regarding 
CRC to improve the outcome. 
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 ﺤﺔﻤﻠﺨﺹ ﺍﻻﻁﺭﻭ
 
ﻴﻌﺘﺒﺭﺴﺭﻁﺎﻥ ﺍﻟﻘﻭﻟﻭﻥ ﻭ ﺍﻟﻤﺴﺘﻘﻴﻡ ﻤﻥ ﺍﻫﻡ ﺍﻻﻭﺭﺍﻡ ﺍﻟﺘﻲ ﺘﺼﻴﺏ ﺍﻟﺠﻬﺎﺯ ﺍﻟﻬﻀﻤﻲ         
ﻭﻫﻭ ﻴﻨﻤﻭ ﻤﻥ ﺍﻟﺨﻼﻴﺎ ﺍﻟﻤﺒﻁﻨﺔ ﻟﻠﻐﺸﺎﺀ ﺍﻟﺩﺍﺨﻠﻲ ﻟﻠﻘﻭﻟﻭﻥ ﻭ ﺍﻟﻤﺴﺘﻘﻴﻡ ﻭ ﻤﻥ ﺠﺭﻴﺒﺎﺕ . ﻟﻼﻨﺴﺎﻥ
  .ﻟﻴﺒﺭﺨﻭﻥ
ﻀﻲ ﺩﺭﺍﺴﺔ ﺍﻟﻲ ﺍﻟﻭﺭﺍﺀ ﻋﻥ ﺴﺭﻁﺎﻥ ﺍﻟﻘﻭﻟﻭﻥ ﻭ ﺍﻟﻤﺴﺘﻘﻴﻡ ﻓﻲ ﺍﻟﻤﺭ  ﻫﺩﻩ        ﺍﻟﺩﺭﺍﺴﺔ
ﻓﻲ ﻤﺴﺘﺸﻔﻲ ﺍﺒﻥ ﺴﻴﻨﺎﺀ  4002  ﻭﺤﺘﻲ ﺩﻴﺴﻤﺒﺭ1002 ﺴﻭﺩﺍﻨﻴﻴﻥ ﻓﻲ ﺍﻟﻔﺘﺭﺓ ﻤﻥ ﻴﻨﺎﻴﺭﺍﻟ
 ﻫﺩﻩ ﺍﻟﺩﺭﺍﺴﺔ ﻫﻭ ﺒﺤﺙ ﺍﻟﺘﻐﻴﻴﺭﺍﺕ ﺍﻟﻤﺭﻀﻴﺔ ﻓﻲ ﺍﻻﻨﺴﺠﺔ ﻓﻲ ﺴﺭﻁﺎﻥ  ﻭ ﺍﻟﻐﺭﺽ ﻤﻥ.ﺒﺎﻟﺨﺭﻁﻭﻡ
ﺍﻟﻘﻭﻟﻭﻥ ﻭ ﺍﻟﻤﺴﺘﻘﻴﻡ ﻭ ﺍﻴﻀﺎ ﺒﺤﺙ ﻋﻼﻗﺔ ﻜل ﻤﻥ ﺍﻟﻌﻤﺭ، ﺍﻟﺠﻨﺱ ﻭ ﺍﻟﻤﺴﻜﻥ ﻤﻊ ﻨﻭﻉ ﺴﺭﻁﺎﻥ 
  .ﺍﻟﻘﻭﻟﻭﻥ ﻭ ﺍﻟﻤﺴﺘﻘﻴﻡ
ﻭ ﻨﺴﺒﺔ .  ﻤﻥ ﺍﻟﻨﺴﺎﺀ44 ﻤﻥ ﺍﻟﺭﺠﺎل ﻭ 65 ﻤﺭﻴﺽ ﻤﻨﻬﻡ 001ﺍﻟﺩﺭﺍﺴﺔ ﺘﻀﻤﻨﺕ         
، ﻭ ﻤﺘﻭﺴﻁ ﺍﻋﻤﺎﺭ ﺍﻟﻤﺭﻀﻲ ﻴﺘﺭﺍﻭﺡ ﻤﺎ 1.1: 1 ﻨﺴﺒﺔ ﺍﻟﻤﺭﺽ ﻓﻲ ﺍﻟﺭﺠﺎل ﻤﻘﺎﺭﻨﺔ ﺒﺎﻟﻨﺴﺎﺀ ﻫﻲ
  . ﺴﻨﺔ58 ﺴﻨﺔ ﺍﻟﻲ 41ﺒﻴﻥ 
ﻤﻥ % 33)        ﻭ ﻟﻘﺩ ﻭﺠﺩﻨﺎ ﻓﻲ ﻫﺩﻩ ﺍﻟﺩﺭﺍﺴﺔ ﺒﺎﻥ ﻫﺩﺍ ﺍﻟﻤﺭﺽ ﻴﺤﺩﺙ ﻤﺒﻜﺭﺍ ﺒﻴﻥ ﺍﻟﺴﻭﺩﺍﻨﻴﻴﻥ
ﻓﻲ ﻜل % 77)ﻭﺜﻪ ﻓﻲ ﺍﻟﺠﺎﻨﺏ ﺍﻻﻴﺴﺭ ﻤﻥ ﺍﻟﻘﻭﻟﻭﻥﻭ ﻴﺘﺭﻜﺯ ﺤﺩ( ﺘﺤﺕ ﺴﻥ ﺍﻻﺭﺒﻌﻴﻥﺍﻟﻤﺭﻀﻲ 
ﻭ ﻗﺩ ﻜﺎﻥ ﻨﺯﻑ (. ﻤﻥ ﺍﻟﻤﺴﺘﻘﻴﻡ، ﺍﻟﻘﻭﻟﻭﻥ ﺍﻟﺴﻴﻨﻲ، ﻭ ﻤﻨﻁﻘﺔ ﺍﻟﺘﺤﺎﻡ ﺍﻟﻤﺴﺘﻘﻴﻡ ﻤﻊ ﺍﻟﻘﻭﻟﻭﻥ ﺍﻟﺴﻴﻨﻲ
ﺘﺭﺍﻭﺤﺕ %(. 67)ﻲ ﻤﺭﻀﻲ ﺴﺭﻁﺎﻥ ﺍﻟﻘﻭﻟﻭﻥ ﻭ ﺍﻟﻤﺴﺘﻘﻴﻡ ﻤﻥ ﺍﻻﻋﺭﺍﺽ ﺍﻟﻐﺎﻟﺒﺔ ﻋﻠﺍﻟﻤﺴﺘﻘﻴﻡ
ﻴﺔ ﺍﻟﻤﺭﻀﻲ ﻜﺎﻨﺕ ﻓﺘﺭﺓ ﺍﻋﺭﺍﻀﻬﻡ ﻲ ﺍﺜﻨﻲ ﻋﺸﺭ ﺸﻬﺭﺍ، ﺒﻴﻨﻤﺎ ﻏﺎﻟﺒﻓﺘﺭﺓ ﺍﻻﻋﺭﺍﺽ ﻤﺎ ﺒﻴﻥ ﺸﻬﺭ ﺍﻟ
  .ﻋﻥ ﺍﻟﺴﺘﺔ ﺍﺸﻬﺭﺘﻘل 
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 ﻤﻥ ﻫﺩﺍ ﺍﻟﺴﺭﻁﺎﻥ، ﻭ ﻗﺩ ﻜﺎﻥ ﺒﺎﻟﺭﺠﻭﻉ ﺍﻟﻲ ﺍﻟﺸﺭﺍﺌﺢ ﺘﻡ ﺍﻟﺘﻌﺭﻑ ﻋﻠﻲ ﺨﻤﺴﺔ ﺍﻨﻭﺍﻉ        
 ﻤﺭﻀﻲ ﺒﺎﻟﺴﺭﻁﺎﻥ ﺍﻟﻐﺩﺩﻱ 31، %(47)ﺎ ﻟﺩﻴﻪ ﺴﺭﻁﺎﻥ ﻏﺩﺩﻱ  ﻤﺭﻴﻀ47 ﺘﻘﺴﻴﻤﻬﺎ ﻜﺎﻻﺘﻲ
 ﻤﺭﻀﻲ ﻟﺩﻴﻬﻡ ﺍﻟﺴﺭﻁﺎﻥ ﺍﻟﺤﻠﻴﻤﻲ 5، %(7) ﻤﺭﻀﻲ ﺒﺎﻟﺴﺭﻁﺎﻥ ﺍﻟﺨﺎﺘﻤﻲ 7، %(31 )ﺍﻟﻤﺨﺎﻁﻲ
  %(.1)، ﻭ ﻤﺭﻴﺽ ﻭﺍﺤﺩ ﺒﺎﻟﺴﺭﻁﺎﻥ ﺍﻟﻤﺘﺤﻭل ﺍﻭ ﺍﻻﺭﺘﺩﺍﺩﻱ%(5)
 ﺍﻟﺨﺼﺎﺌﺹ         ﻭ ﻟﻘﺩ ﺨﻠﺼﺕ ﻫﺩﻩ ﺍﻟﺩﺭﺍﺴﺔ ﺍﻟﻲ ﺍﻥ ﺍﻟﺴﻭﺩﺍﻥ ﻴﺸﺎﺭﻙ ﺍﻟﺩﻭل ﺍﻟﻨﺎﻤﻴﺔ ﻓﻲ ﺒﻌﺽ
 ﻭ ﺘﺭﻜﺯﻩ ﺍﻟﺒﻴﺌﻴﺔ ﻟﺴﺭﻁﺎﻥ ﺍﻟﻘﻭﻟﻭﻥ ﻭ ﺍﻟﻤﺴﺘﻘﻴﻡ ﻭ ﺍﻟﺘﻲ ﺘﺘﻤﺜل ﻓﻲ ﺍﻟﺤﺩﻭﺙ ﺍﻟﻤﺒﻜﺭ ﻟﻬﺩﺍ ﺍﻟﻤﺭﺽ،
ﻭ ﺍﻴﻀﺎ ﺘﻁﺭﻗﺕ . ﻓﻲ ﺍﻟﺠﺎﻨﺏ ﺍﻻﻴﺴﺭ ﻤﻥ ﺍﻟﻘﻭﻟﻭﻥ ﻤﻤﺎ ﻴﺘﻁﻠﺏ ﺍﻟﻤﺯﻴﺩ ﻤﻥ ﺍﻟﺒﺤﺙ ﻟﻤﻌﺭﻓﺔ ﺍﻻﺴﺒﺎﺏ
ﺍﻟﺩﺭﺍﺴﺔ ﺍﻟﻲ ﺍﻫﻤﻴﺔ ﺍﻟﺘﺜﻘﻴﻑ ﺍﻟﺼﺤﻲ ﻭ ﺒﺭﻨﺎﻤﺞ ﺍﻟﻔﺤﺹ ﺍﻟﻁﺒﻲ ﺍﻟﺩﻭﺭﻱ ﻟﺴﺭﻁﺎﻥ ﺍﻟﻘﻭﻟﻭﻥ ﻭ 
  .ﺴﺘﻘﻴﻡ ﻤﻥ ﺍﺠل ﺍﻟﻭﺼﻭل ﺍﻟﻲ ﻨﺘﺎﺌﺞ ﺍﻓﻀلﺍﻟﻤ
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INTRODUCTION & LITERATURE REVIEW 
 
 
          Colorectal cancer (CRC) is a major health problem 
throughout the world, with the highest incidence rates in North 
America, Western Europe, Australia and Newsland.(1)It is the fourth 
most common internal malignancy and is second to carcinoma of 
the lung as a cause of cancer death.(2) 
         Virtually 90%-98% of all cancers in the large bowel are 
adenocarcinoma.(1,3,4,5)The remainder are neoplasms of the 
neuroendocrine cells, mainly carcinoid tumors; direct invasion of 
the colon and  rectum by other visceral malignancies, such as 
carcinoma of the prostate, urinary bladder and uterus;  metastatic 
tumors, such as malignant melanoma;(4)lymphomas and 
mesenchymal tumors.(6) 
          Colorectal cancer usually occurs over the age of 50 years.(4) 
In Sudan it was reported to affect younger age group and about 
30% of the lesions were of the mucoid  & undifferentiated types.(7) 
         The main precursor lesion for CRC is adenoma, which is 
readily detected& treated by endoscopic techniques. While most of 
adenomas are polypoid, flat and depressed lesions may be more 
prevalent than previously recognized.(8) Non neoplastic polyps 
(hyperplastic, juvenile, hamartomatous, and lymphoid polyps) are 
  2
not considered precancerous unless they occur in polyposis 
syndromes (juvenile polyposis and hyperplastic polyposis).(6,9,10,11) 
1.1.Definition: 
      Colorectal  cancer (CRC) is a disease in which cells in the 
colon or rectum become abnormal & divide without normal control 
or order, forming a mass called tumor.(12)It arises from the 
epithelium lining the inner surface of the colon &rectum and from 
the crypts of Leiberkühn.(13) 
1.2.Normal Anatomy: 
  Normally the large bowel comprises the terminal 1-1.5m of 
the gastrointestinal tract and is subdivided into: cecum, ascending 
(right) colon, transverse colon, descending (left) colon, sigmoid 
colon, and rectum. The hepatic flexure is at the junction of the 
ascending and the transverse colon, and the splenic flexure is at 
the junction of the transverse and descending colon. The rectum 
forms the distal 8-15cm of extraperitoneal large bowel. 
Histologically, the large bowel wall is composed of 4 layers which 
are (from lumen outwards):(14) mucosa, submucosa,  muscularis 
externa, and serosa (or, in the rectum, perimuscular tissue).The 
mucosa has 3 components: epithelium, lamina propria, and 
muscularis mucosa. The mucosal surface is covered by a single 
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layer of low columnar to cuboidal epithelium which is composed of 
absorptive cells (with basally located nuclei, mucin negative 
acidophilic cytoplasm, and apical striations) and goblet cells 
(contain mucin granules). Crypts of Leiberkühn open into the 
mucosal surface. They have tubular shape and arranged in parallel 
to each other, and their epithelium contains mature absorptive 
cells, undifferentiated precursor cells, goblet cells, endocrine cells, 
and paneth cells. Both the precursor and the endocrine cells 
predominate at the base of crypts. The paneth cells are identified 
by their numerous eosinophilic secretory granules, and they are 
only present in the cecum and right colon.(14) 
          The lamina propria consists of connective tissue cells & 
fibers. It contains blood vessels, lymphatics, nerves &lymphoid 
follicles which extend from the mucosa through the muscularis 
mucosa into the submucosa.(14) 
   The submucosa composed of loose connective tissue contains 
cells similar to those in the lamina propria, and also contains the 
Meissner’s plexus.(14) 
  The muscularis externa includes a circular inner layer and a 
longitudinal outer layer of muscles, with the myenteric plexus of 
Auerbach between them.(14) 
  4
  The serosa is composed of a single layer of flattened to 
cuboidal mesothelial cells and the subjacent fibroblastic tissue. 
The large bowel is supplied by branches of the superior mesenteric 
artery (from the cecum to the splenic flexure) and the inferior 
mesenteric artery (distal to the splenic flexure). The lower portion 
of the rectum is irrigated by the middle and inferior rectal arteries, 
which are branches of the internal iliac artery (14). 
  The lymphatic drainage of the colon is mainly through the 
mesentery into the paracolic lymph group, then to intermediate 
nodal group, to central group, and finely to the paraortic chain. The 
lymphatic drainage of rectum is toward the inferior mesenteric 
artery nodes, the superior haemorroidal chain, the hypogastric and 
the common iliac nodes.(14)   
1.3. Epidemiology: 
  Colorectal cancer is an important health problem. There are 
one million new cases diagnosed worldwide each year and 
approximately half a million death (15), making this cancer the fourth 
most common incident cancer and cause of death throughout the 
world. The developed countries account for >63% of the total 
global incidence. High-risk areas include North America, Europe 
and Australia. Central and South America, Africa and Asia are 
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areas with low risk factors.(16)CRC is slightly more common in  
males. Sporadic cases of CRC occur over the age of 50 years(4), 
with peak incidence at 60-70 years & fewer than 20% occur before 
the age of 50 years. When CRC is found in a young person, pre-
existing ulcerative colitis or one of the polyposis syndromes must 
be suspected.(3) 
1.4. Etiology & Pathogenesis: 
  CRC either occur on a preexisting adenoma or on a normal 
mucosa without evidence of adenomatous precursors.(3) The exact 
cause of CRC is unknown, but there are many risk factors which 
include: 
1- Age and sex: CRC is more common in males above the age of 
50 years.(4,17)       
2- Inflammatory bowel diseases: as chronic ulcerative colitis (U.C) 
is associated with increased risk of CRC. The lesion that occurs 
in U.C. tend to be flat and invasive, and is difficult to be detected 
endoscopically at an early stage.(4)So patients with U.C. are  
commonly screened every one to two years by colonoscopy & 
biopsy to look for dysplasia.(18)    
3- Family history of CRC or adenomatous polyps: In general, closer 
familial relationship to affected relatives, younger age of affected 
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relatives, and larger number of affected relatives all increase the 
risk of CRC.(18)About 5%-10% of patients with CRC have an 
inherited genetic abnormality that causes the cancer. These 
abnormalities are Familial Adenomatous Polyposis (FAP) & 
Hereditary Non Polyposis Colorectal Cancer (HNPCC), and they 
should be excluded by careful family history.(19)  
• Familial Adenomatous Polyposis (FAP): An autosomal 
dominant syndrome that result from defect in the 
adenomatous polyposis coli (APC) gene.(20)It is characterized 
by presence of hundreds of polyps which occur at young age 
and develop into CRC by the age of 40 years if preventive 
surgery is not done.(21,22)About 1% of all CRC are due to this 
syndrome.(19)   
• Hereditary Nonpolyposis Colorectal Cancer (HNPCC): Is an 
autosomal dominant syndrome that is a result of germline 
mutations in mismatch repair genes (genes that code for 
proteins responsible for correcting errors during DNA 
replication). It is characterized also by presence of few polyps, 
but not hundreds, at young age & then developed into 
malignancy between the ages of 40 & 50 years.(23) 
4- Dietary factors: Research is going on the role of dietary factors 
such as red meat especially overcooked or processed, high fat 
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intake, low fiber diet, high refined carbohydrates, decreased 
intake of protective micronutrients, obesity, alcohol 
consumption, & deficiency of calcium & folate. All these factors 
increase the incidence of CRC risk.(16,24,25,26,27,28,29,30,31,32) It is 
theorized that reduced fiber content lead to decreased stool 
bulk, increased fecal transit time in the bowel, and altered 
bacteria flora of the intestine. Potentially toxic byproducts of 
carbohydrate degradation are therefore present in higher in the 
small stools and are held in contact with the colonic mucosa for 
longer period of time. Moreover high cholesterol intake in the 
red meat enhances the synthesis of bile acids by the liver, 
which, in turn, may be converted into potential carcinogens by 
intestinal bacteria. Refined diet also contains less vitamin A, C, 
and E, which may act as oxygen scavengers.(3) 
5- Other risk factors: 
-  It has been reported that the use of aspirin, 
postmenopausal female hormone therapy, and oral 
contraceptive pills are associated with low risk for 
CRC.(33,34,35,36,37,38) 
- Low physical activity & cigarette smoking are associated 
with high tendency to develop CRC.(39,40,41,42,43,44) 
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- Infection with Helicobacter pylori, cytomegalovirus, or 
human polyoma virus JCV was reported to be  associated 
with CRC.(45-47) 
- Hyperinsulinaemia is associated with increased risk of 
endometrial, colorectal, & breast carcinoma. The insulin 
acts as growth factor for tumor formation.(48) 
     However 75% of all CRC occur in people with no known 
predisposing factors for the disease. This makes early detection 
and management with different screening modalities is an 
important mean for significant reduction in CRC incidence and 
mortality.(17)  
1.5. Genetics of CRC: 
          Most CRC occurs sporadically in absence of well-defined 
familial syndromes (3), while the remainder of CRC occur in patient 
with inherited germline defects.(4) Regardless of the inciting event, 
there are two pathogenically distinct pathways for the development 
of CRC(49), both of which involve stepwise accumulation of multiple 
mutations. However the genes involved and mechanisms by which 
the mutations accumulate are different.(3)These pathways are: 
(1)  Adenoma-carcinoma sequence: characterized by chromosomal 
instability that result in accumulation of mutations in a series of 
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oncogenes and tumor suppresser genes. These genes include: 
APC gene, K-RAS gene, SMAD2&SMAD4 genes, and 
P53gene.(3) 
(2)  Microsatellite Instability Pathway: characterized by genetic 
lesions in DNA mismatch repair genes. It is involved in 10%-
15% of sporadic cases & in the HNPCC syndrome.(3) 
1.6. Localization: 
         Most CRC are located in the sigmoid colon and rectum, but 
there is evidence in changing distribution in the recent years, with 
increased proportion of more proximal carcinoma.(50) Molecular 
pathology has also shown site differences: tumors with high levels 
of microsatellite instability (MSI-H) or RAS proto-oncogene 
mutations are more frequently located in the cecum, ascending 
colon & transverse colon.(51,52,53) 
1.7. Metastasis & Mode of spread:   
   Colorectal cancer arises in the mucosa and tends to 
spread to other organs through one of the following routes:(54) 
(1)  Direct extension of the tumor through all layers of the colon 
wall to the adjacent structures or organs. 
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(2)  Haematogenous: through  the blood to the liver 
(commonly), lungs, brain, adrenals, kidney, bone and others. 
This route is associated with poor prognosis. 
(3) Lymphatic: through the submucosal blood vessels to the 
regional lymph nodes. 
(4) Transcelomic: through the peritoneal cavity (54). 
1.8. Diagnosis: 
Clinical picture: 
          The presentation of large bowel malignancy generally falls 
into three categories: insidious onset of chronic symptoms, acute 
onset of intestinal obstruction, or acute perforation. The most 
common is that of the insidious onset of chronic symptoms(2), 
which are: 
  Rectal bleeding, chronic anaemia, change in bowel habits, 
abdominal or rectal pain.(54) Less common symptoms include 
weight loss, palpable mass, malaise, fever, symptoms of urinary 
tract involvement, mucus discharge, obstruction or perforation of 
the colon, acute appendicitis (from obstruction of the appendiceal 
lumen by a cecal tumor) or signs of distant metastasis to the liver, 
lungs or brain.(2,54)Rectal bleeding is visible in lesions of the 
sigmoid colon and rectum, and will be the cause of anaemia 
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.Alteration in bowel habits(constipation &diarrhoea)are more 
common with left colon or more distal tumors, because of narrow 
lumen and more solid stool that traverse the segment containing 
the tumor. Abdominal pain is crampy or constant.(54) Left-sided 
obstructing lesions may present with cramping abdominal pain 
associated with nausea & vomiting.(2) Presence of peritonitis 
indicates colonic perforation. Palpable mass, signs of distant 
metastasis and weight loss are associated with poor prognosis.(54) 
Screening:                                       
   Screening means checking for health problem before they 
cause symptoms.(12) Because early detection greatly influence 
survival in CRC, mass population screening has been 
recommended in many high-risk populations. High-risk patients 
include patients over 40 years of age, patients with Familial 
Adenomatous Polyposis (FAP) and Hereditary Non Polyposis 
Colon Cancer (HNPCC), and patients with chronic ulcerative colitis 
(U.C).(4)Currently, it is estimated that screening of average risk 
people over the age of 50 would reduce the mortality of CRC by 
50%.(55) 
  Screening for sporadic CRC is unsatisfactory. Several 
different screening methods have been advocated (4): 
 
  12
a) Faecal Occult Blood Testing(FOBT) annually: Fecal Occult 
Blood Test is nonspecific test that fail to detect many small 
cancers and precancerous lesions.(56)But a positive annual or 
biannual FOBT that is followed by complete diagnostic 
evaluation of the colon will reduce the number of deaths caused 
by CRC.(57),(58) 
b) Flexible sigmoidoscopy every five years: Is an examination of 
the rectum &lower colon using sigmoidoscope.(12)The 
effectiveness of this method as a screening tool depends on its 
ability to detect cancers & adenomatous polyps in average risk 
asymptomatic patients with negative FOBT.(59) If sigmoidoscopy 
detects polyps, it should be followed by colonoscopy.(60)  FOBT 
annually accompanied by sigmoidoscopy every five years is 
recommended by American Cancer Society (ACS)&other 
experts.(61)   
c) Double Contrast Barium Enema(DCBE)every five to 10 years:          
Is series of X-Rays of the entire colon & rectum.(12) The efficacy 
of barium enema in preventing CRC has not been 
evaluated.(59)Single-column barium enema is less sensitive than 
DCBE, so if it is used as a screening tool, it should be combined 
with flexible sigmoidoscopy.(18)If lesions are detected by barium 
enema the patient require colonoscopy.(59)   
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d) Colonoscopy every 10 years: Colonoscopy is examination of 
rectum & entire colon using colonoscope.(12) It allows detection  
& removal of premalignant & malignant lesions through out the 
entire colon & rectum(12,59), and so reduces deaths from CRC.(62)   
e) Genetic testing: Is recommended only for: (1) Those with 
familial polyposis syndrome & HNPCC to see whether they 
have the inherited genetic defect. (2) Patients with sporadic 
CRC who satisfy the Amsterdam Criteria for HNPCC,(4) which 
are: a) At least 3 family members with CRC, at least 2 being 
first degree relatives. b) At least 2 generations with CRC. c) At 
least one CRC patient younger than 50 years old at diagnosis. 
Over 70% of families that meet these criteria have genetic 
mutations associated with HNPCC.(63)  
      There are new tests under study for CRC screening:  
(1)  Virtual Colonoscopy (Computed Tomographic Colonoscopy). 
(2)  Genetic testing of stool sample.(12) 
Diagnostic Studies: 
          Colonoscopy with biopsies is best; proctosigmoidoscopy 
gives limited data due to shorter length of scope, and DCBE is 
useful but requires colonoscopy if lesions are seen.(1)Brush 
cytology has been described as useful in diagnosis of rectal 
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cancer, but now is not recommended because of high cost & rare 
false positive diagnosis.(4) 
Lab Studies: 
          Complete blood count with differential, showing anaemia in 
right-sided tumors due to chronic blood loss; chemistry panel 
including liver and renal functions.(1) 
Preoperative Studies: 
          Chest X-Ray (CXR); serum Carcinoembryonic Antigen 
(CEA) level; metastatic search if suspected; abdominal CT & 
radionuclide scanning are costy, so have no role in majority of 
patients.(1)  
1.9. Pathologic diagnosis: 
          The diagnosis of CRC is established by histologic 
examination of a biopsy specimen which obtained endoscopically 
or, rarely, intraoperatively when the endoscopy is impossible 
because of tight strictures.(4) 
Gross: 
          CRC may be exophytic/fungating with predominantly 
intraluminal growth, endophytic/ulcerative with predominantly 
intramural growth, diffusely infilterative/linitis plastica with subtle 
endophytic growth, and annular with circumferential involvement of 
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the colorectal wall & constriction of the lumen.(6) Right-sided colon 
cancers tend to be polypoid, exophytic masses that project from 
the wall into the lumen. Left-sided colon cancers tend to be annular 
with mucosal ulceration & thickening of the wall causing luminal 
narrowing. Rectal cancers are exophytic or ulcerative.(4) But 
overlap among these types is common.(6) 
          The incidence trends of CRC differ for each subsite (64) as 
follows: the cecum & ascending colon, 22%; transverse colon,11%; 
descending colon, 6%; rectosigmoid, 55%; &other sites, 6%.(3) In 
other words about 50% of CRC occurs in  the rectosigmoid 
area.(14) 
          In cross section, grayish white tissue is seen replacing the 
bowel wall. Highly mucinous tumors have a gelatinous, glaring 
appearance, with mucus separating the layers of the bowel wall.(14) 
Histological types: 
          The internationally accepted histologic classification of CRC 
proposed by the World Health Organization (WHO) is 
recommended by the College of American Pathologists (CAP) and 
is usually used in pathology reports.(65,66) Medullary carcinoma, 
which previously classified as an undifferentiated carcinoma, has 
been added to the revised WHO classification.(67) 
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* World Health Organization classification of colorectal 
carcinoma:(6) 
- Adenocarcinoma insitu/severe displasia. 
- Adenocarcinoma. 
- Mucinous (colloid) adenocarcinoma. 
- Signet-ring cell carcinoma. 
- Squamous cell (epidermoid) carcinoma. 
- Adenosquamous carcinoma. 
- Small cell (oat-cell) carcinoma. 
- Medullary carcinoma. 
- Undifferentiated carcinoma. 
- Others (e.g. papillary carcinoma). 
Adenocarcinoma: 
          About 85% of CRC are well and moderately differentiated 
Adenocarcinoma. These are composed of irregularly infiltrating 
malignant glands. The cells are columnar & have elongated “cigar-
shaped” nuclei. The invasive tumor is surrounded by a 
desmoplastic response. There is focal necrosis & variable mitotic 
activity.(4) 
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Mucinous adenocarcinoma:  
          Comprises 10% of CRC and include signet-ring cancers. 
The mucinous adenocarcinoma is characterized by extracellular 
mucin with the tumor cells floating in it.(68)The definition of 
mucinous carcinoma is variable: some say that 50% of the lesion 
must be mucinous(66), where as others say that 75% of the lesion 
must be mucinous.(69,70) 
Signet-ring cell carcinoma: 
          Defined by the presence of >50% of tumor cells with 
prominent intracytoplasmic mucin.(71) It can occurs in the mucin 
pools of mucinous adenocarcinoma.(6) Signet-ring carcinoma has a 
poor prognosis. 
Squamous/Adenosquamous cancers: 
          Are very rare & are associated with U.C, schistosomiasis, 
and pelvic irradiation.(14)To classify a lesion as adenosquamous 
carcinoma, occasional foci of squamous differentiation must be 
present.(6) Certain criteria must be present to diagnose primary 
CRC as squamous or adenosquamous: (1) No other sites of 
squamous carcinoma in the body. (2) No involvement of 
colacogenic or squamous-lined mucosa.(72) 
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Small cell carcinoma: 
          Rare and is about <1% of CRC. It is a malignant 
neuroendocrine tumor that is similar histologically & biologically to 
small cell (oat cell) carcinoma of the lung. As signet-ring 
carcinoma, the small cell carcinoma has unfavorable 
prognosis.(67,68) 
Medullary carcinoma: 
         Uncommon & about 1% of CRC.(68) It is non-gland forming 
carcinoma that previously  had been classified as undifferentiated 
carcinoma by the WHO system, but now known to be associated 
with microsatellite instability and/or HNPCC syndrome.(67) 
Histologically medullary carcinoma has pushing borders & is 
composed of uniform, rounded cells which have small to medium-
sized nuclei & prominent nucleoli. It exhibits numerous mitosis & 
brisk lymphocytic infiltrate.(68,73) Medullary carcinoma has a good 
prognosis.(74) 
Undifferentiated carcinomas: 
          These are tumors lack morphological evidence of 
differentiation beyond that of epithelial tumor and have variable 
histological features.(75) 
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Unusual forms of CRC: 
      Are very rare &for example:  
? Papillary carcinoma: the carcinoma forms papillations with 
fibrovascular cores & epithelial tufts.(67) 
? Spindle cell (sarcomatoid or metaplastic) carcinoma.(76) 
? Clear cell adenocarcinoma: resemble renal cell adenocarcinoma, 
but differentiated from it by presence of high level of 
Carcinoembryonic Antigen (CEA) in the former.(14),(77)   
? Basaloid (colacogenic) carcinoma: similar to it is anal 
counterpart,& has been reported on a few occasions in the 
colorectum.(14)   
? Carcinoid tumor: of the large bowel is more common in the 
rectum.(14) It is composed of small & uniform cells with rounded 
nuclei with granular chromatin. The cells arranged in nests or 
trabecular pattern.(4)   
?  Adenocarcinoma-carcinoid tumor: are very rare in the colorectum. 
Composed of approximately equal amounts of adenocarcinoma & 
well differentiated carcinoid tumor.(4) 
? Choriocarcinomatous differentiation: rare cases of 
adenocarcinoma with areas of choriocarcinoma have been 
reported.(68)  
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? Lymphomas: are less frequent than in the small intestine & 
stomach.(14) 
Staging: 
       Pathologic staging is an expression of the degree of invasion 
& metastatic spread of the tumor.(4) It is based on the size of the 
primary lesion, its extent of spread to regional lymph nodes, and 
the presence or absence of distant metastasis.(3) 
      Three different systems for staging CRC have been developed 
over years(4): 
(1) Duke’s System(78)*: is the simplest & is widely used in 
Europe.(4) 
• Duke’s Classification of carcinoma of the colon & rectum: 
Stage A: cancer restricted to colorectal wall. 
Stage B: the cancer invades outside the muscularis externa. 
Stage C: cancer with positive nodes. 
Stage D: distant metastasis. 
(2) Astler-Coller System (79)**: Modified Duke’s System. It is used in 
the United States in addition to the Duke’s System. It provides 
better distinction between minimally invasive tumors in term of 
their nodal status.(4) 
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** Astler-Coller Classification of carcinoma of the colon and 
rectum: 
Stage A: lesion limited to the mucosa. 
Stage B1: lesion involves muscularis propria, but does not    
                penetrate through it; uninvolved nodes. 
Stage B2: lesion penetrates through the muscularis propria, 
                uninvolved nodes. 
Stage C1: extending into the muscularis propria, but not  
                penetrating through it; involved nodes. 
Stage C2: penetrating through the muscularis propria; 
                Involved nodes. 
Stage D: distant metastatic spread 
(3)TNM (Tumor, Node, Metastasis) System(80)***: This system 
had been advocated by American Joint Committee on Cancer 
(AJCC) and Union Internationale Contre Le Cancer 
(UINCC),and is recommended by the College of American 
Pathologists (CAP).(65,81)It is more accurate, but too 
cumbersome for general use.(4) Currently the TNM system is 
widely used, & is internationally accepted.(67) 
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*** TNM Classification of carcinoma of the colon & rectum: 
T: primary tumor. 
     TX: primary tumor can not be assessed. 
     Tis: carcinoma insitu (intraepithelial) or intramucosal     
(lamina propria invasion). 
     T1: tumor invades submucosa. 
     T2: extending into the muscularis propria, but not penetrating 
           through it. 
     T3: penetrating through the muscularis propria into the serosa 
           into non-peritonealized paracolic or perirectal tissues. 
     T4: tumor directly invades other organs or structures and/or   
           perforates visceral peritoneum.            
N: regional lymph nodes. 
      NX: regional lymph nodes can not be assessed. 
      N0: no regional lymph node metastasis. 
      N1: metastasis in 1 or 3 lymph nodes. 
      N2: metastasis in 4 or more lymph nodes. 
M: distance metastasis. 
      MX: distant metastasis can not be assessed. 
      M0: no distant metastasis. 
      M1: distant metastasis. 
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Stage grouping: 
         Stage 0           Tis           N0          M0  
         Stage I            T1           N0          M0     
          T2           N0          M0 
         Stage  ІΙ           T3             N0         M0 
          T4            N0         M0 
         Stage ΙΙΙ        any T        N1          M0 
                               any T        N2         M0 
         Stage ΙV        any T       any N     M1 
Tumor Grading: 
          Grading of a tumor is an expression of the aggressiveness 
of the neoplasm. It is based on the degree of differentiation of the 
tumor cells&the number of the mitosis within the tumor.(3) 
          The histological grading of CRC is evaluated subjectively. 
Although a number of grading systems have been suggested in 
the literature, there is no single accepted standard for grading. The 
number of grades & the criteria in each differ among the various 
grading schemes. In some systems, grades are defined on the 
basis of a single microscopic feature, such as the degree of gland 
formation, &in others the grades based on a number of features.(67) 
However, most systems stratify tumors into three or four grades as 
follows: 
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GRADE 1: well differentiated. The glandular structure is   
                  > 95% of the tumor,(6) & is composed of simple tubule 
                   with easily discerned nuclear polarity.(68)  
GRADE 2: moderately differentiated. The glands are  50% - 95%      
                    of the tumor,(6) & are  irregular with barely discernable      
                    or lost nuclear polarity.(68) 
GRADE 3: poorly differentiated. The glandular structure is  
                   5%-50%(6) or absent with loss of the nuclear polarity.(68)  
GRADE 4: undifferentiated,(67) & the glandular structure is <5% of  
                  the tumor.(6)  
          Mucinous adenocarcinoma & signet ring cell carcinomas are 
considered poorly differentiated (grade 3). Medullary carcinoma 
with MSI-H appears undifferentiated.(6) 
          In general a two-typed grading system based solely on 
proportion of gland formation (> or < 50% glands formation) would 
be expected to reduce interobservor variability. This system is as 
follows: 
LOW GRADE: include the well differentiated& moderately 
                        differentiated tumors.(58) 
HIGH GRADE: include poorly differentiated & undifferentiated  
                          tumors.(82) 
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            So the use of a two-typed grading system for CRC is 
advisable, & such system has been recommended by colorectal 
working group of a 1999 Consensus Conference sponsored by the 
College of American Pathologists (CAP).(83) 
1.10.Treatment: 
          The three main types of treatment for CRC are surgery, 
radiation therapy, and chemotherapy.(19) Surgery includes 
segmental resection of the tumor with adequate margins along with 
potentially involved lymph nodes.(4) 
          Newer targeted therapies called monoclonal antibodies are 
now beginning to be used as well. Depending on the stage of the 
cancer, two or more types of treatment may be used at the same 
time, or one after the other.(19) 
♦ Early stage colon cancer: 
            Surgery is initial therapy for choice for localized, potentially 
curable cases.(1) It is either open surgery (colectomy with 
colostomy) or laproscopic resection.(4,84)  
Postoperative radiation and adjuvant chemotherapy with                  
5-Fluorouracil (5-FU) reduce the risk of recurrence.(85,86) 
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•  Early stage rectal cancer: 
        
          Also surgery is the main treatment. Transanal endoscopic 
microsurgery (TEM) is now preferred form of local treatment for 
rectal polyps & stage І rectal cancer that are small & near the 
anus.(4,84) A low anterior resection is for cancers near the upper 
part of the rectum.(19) For cancers in the lower part of the rectum, 
abdominoperitoneal resection with colostomy is done.(4,19) The 
surgery should be followed by chemoradiation which improve 
survival and local control of the tumor.(87)  
         Most studies regimens consist of surgery and postoperative 
chemotherapy with 5-FU & mitomycin within 6 weeks, followed by 
radiation plus concurrent chemotherapy.(88) 
• Metastatic cancer: 
          Is treated by surgery (after preoperative evaluation), 
postoperative radiation (for palliative treatment of symptoms), and 
systemic chemotherapy with various 5-FU based regimens.(1)  
• New developments in treatment of CRC: 
- Drugs being developed to enhance the tumor-killing ability of 
radiation therapy & chemotherapy, and stop the angiogenesis. 
- Gene therapy. 
- Immunotherapy: enhances the body’s immune system to kill 
tumor cells. 
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- Monoclonal antibodies to identify tumor cells for destruction or 
prevent their division. 
- Vaccines: cause the body to produce more antibodies to kill 
cancer cells.(89)  
1.11. Prognosis: 
          The 5-year crude survival rate after curative resection for 
CRC ranges between 40%-60%. Local recurrence and/or regional 
lymph node metastasis occur in over 90% of the failure cases.(14) 
         The prognosis of CRC is affected by a number of clinical 
variables, pathological features, oncogenetic, molecular, & 
immunological variables. The pathologic stage & the factors 
affecting it remain the most prognostic factors.(90) The 5-year 
survival rate are ~90% for Duke’s A, 5o-65% for Duke’s B, and      
15-25% for Duke’s C.(14,90) 
          Poor prognostic factors include: elevated CEA level, which is 
the only consistently predictive clinical feature; mucinous & signet 
ring pattern on histology; bowel wall/ regional lymph node/ 
perineural invasion; evidence of bowel obstruction or 
perforation;(1)DNA ploidy; DCC gene deletion; P53 & Ki-ras 
mutation;(91) mucin associated antigens;(92) growth factors & 
receptors expression.(93)   
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1.12. Recurrence: 
          Is manifested by occurrence of symptoms after 
treatment,(94)& can be:  
(1) Locoregional: the recurrence is in or around the anastomotic 
site. It results from positive surgical margins.(4) 
(2) Peritoneal metastasis: result from seeding of the peritoneal 
cavity by the tumor prior to surgery.(4) 
(3) Distant metastasis: may manifest in lymph nodes more 
proximal to those in the field of initial surgery&elsewhere in 
the body due to haematogenous spread.(4) 
          Recurrence is best detected by: serial serum assays for 
CEA, CT scans, radionuclide liver scans, & regular colonoscopy in 
the first year after surgery.(4,14) 
          Recently, a new blood test for detection of recurrence has 
been announced. This test is called GCC-B1TM.It tests for the 
presence of the protein guanylyl cyclase C in the blood, which is 
normally only found in the intestine. This test has the ability to 
detect 90%-100% of CRC metastasis.(95)  
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OBJECTIVES 
 
 
General objectives: 
        To study the pattern of patients with CRC in Khartoum State, 
Sudan; from January 2001 through to December 2004 with view to 
determine various epidemiological & clinicopathological features of 
this malignancy. 
  
Specific objectives: 
1- To determine the histopathological patterns of CRC. 
2- To determine the residency distribution, clinical presentation & 
relation of CRC with age & sex.  
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METHODOLOGY 
2.1. Study design:        
       A descriptive retrospective study. 
2.2. Study field:          
Ibn Sina Hospital at Khartoum, Sudan. It is specified for 
renal & gastrointestinal diseases. It receives patients from different 
regions of Sudan for diagnosis & management. 
2.3. Study Population:         
All cases of colorectal cancer presented to Ibn Sina Hospital 
between January 2001 through to December 2004. 
2.4. Inclusion Criteria:  
Colorectal cancer patients who under-went endoscopic and 
histopathological studies for diagnosis, with or without laboratory 
and radiological studies. 
2.5. Exclusion Criteria:        
 Colorectal cancer patients who had no histopathological 
slides in the histopathology lab of the hospital. 
2.6. Tools of data collection:      
 Data were collected from the patients’ request forms into a 
predesigned questionnaire with detailed history and investigations. 
The patients in this study had been diagnosed by histological 
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examination of surgical or endoscopic biopsies which had been 
processed to provide slides for microscopic examination. The 
processing include fixation (in 10% formalin), dehydration (by 
different concentrations of alcohol), clearing (using xylene), &   
impregnation (with paraffin wax). Then the tissues were blocked by 
transferring them from the final wax bath into a mold filled with 
molten wax. The block was then quickly cooled. The tissue was cut 
by microtome, & the cut sections were flooded on a mounting bath. 
Then the sections were mounted on an ordinary slides, put in a hot 
oven or hot plate to remove the wax & finally stained by routine H 
& E method.  The slides of the histopathological diagnosis for 
patients were collected& reviewed to: confirm the CRC diagnosis; 
determine the histopathological type of the tumor using the WHO 
classification of CRC; and grade the tumor using the well 
differentiated, moderately differentiated, poorly differentiated, 
&undifferentiated Grading System.  
2.7. Statistics: 
The data were analyzed using computer S.P.S.S program, 
version 10. 
 
 
 
 
 
  32
RESULTS 
 
There were 123 patients with CRC during the 4 years study.  
When the slides reviewed, 23 patients had no available slides & so  
were excluded from this study. The remainders (100 cases) were 
analyzed. 
3.1. Characteristics of the studied patients: 
3.1.1. Age distribution: 
 
          The ages ranged from 14-85 years with a mean of 49.89± 
16.86.Thirty-three (33%) patients were below 40 years of age. The 
youngest patient was 14 years old. The peak age of incidence was 
> 60 years (Figure 1). 
3.1.2.Sex distribution: 
          Fifty-six (56%) patients were males compared to 44 (44%) 
females (Figure 2). The colon cancer cases were 45 cases, while 
those of the rectum were 55 cases. The 45 colon cancer cases 
distributed almost equally between males & females (23 males & 
22 females), where as rectal cancers (55 cases) encountered more 
among males (33 cases) compared to females (22 cases). As a 
result of these findings, the male to female incidence rate ratio 
(R.R) for colon cancer was 1:1 and for rectal cancer was 1.5:1. For 
all CRC it was 1.1:1 (Table 1). 
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          The incidence rate for males increases slowly with age until 
reaching peak at the age of 60 & over, while females had two 
peaks, one at the age group 20-<40, & the other at the age group 
60 & over (Figure 3). 
3.1.3.Residency distribution in CRC: 
         As regard to residency, seventy-four (74%) patients were 
from the middle of Sudan (more than two thirds of them were   
from Khartoum), thirteen (13%) patients were from the North, 
eleven (11%) patients were from the West, two (2%) patients were 
from the East, and no one was from the South (Figure 4). 
3.2. Distribution of the clinical symptoms in the 
studied patients: 
          Table 2 shows the various presentations of CRC in the 
studied patients. Rectal bleeding represented the majority (76%) of 
the symptoms. About 90% of patients with rectal cancer presented 
with frank rectal bleeding on presentation. The duration of the 
symptoms varied from one to twelve months in the majority of 
patients. Among the total, 61.2% of patients had symptoms ≤6 
months duration, while 38.7% of patients had symptoms of >6 
months. 
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3.3. Subsite distribution of CRC in the studied 
patients: 
         The majority of the tumors arising from the rectum, sigmoid 
colon & rectosigmoid junction (77%), the transverse colon was the 
least involved site (2%) (Figure 5).  
3.4  . Histopathological characteristics of CRC in the 
studied patients: 
3.4.1.Histological patterns: 
          The diagnosis of CRC in this study is based on 
histopathological examination of endoscopic biopsies, combined 
with U.S. examination. The serum level of CEA had been reported 
in only 3 patients. 
         Adenocarcinoma was the most common tumor seen in 74% 
of cases. 13 (13%) were Mucinous adenocarcinoma, 7 (7%) Signet 
ring cell carcinoma, 5 (5%) Papillary carcinoma, & 1 (1%) 
anaplastic carcinoma. (Figure 6). 
3.4.2.Grading: 
         The moderately differentiated adenocarcinoma represented 
the majority of CRC cases (38.3%), followed by the poorly 
differentiated adenocarcinoma, & then the well-differentiated 
adenocarcinoma became the least (Table 3). 
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3.5. Relationship between the histological patterns of 
CRC & the age groups in the studied patients: 
        The adenocarcinoma was predominant (43.2%) among 
those ≥ 60 years of age compared to the other age groups. The 
mucinous type was highest (40%) and equally distributed between 
the age groups 20-<40 & ≥ 60 years. The signet ring carcinoma 
was more common (71%) among the age group 20-<40 years. 
Finally the anaplastic type was found to be confined to the age 
group ≥ 60 years (Figure 7).  
3.6. Relationship between the histological patterns & 
the sex in the studied patients: 
         All the histological types of CRC were found to be more in 
males than females. No female was reported with the anaplastic 
type (Figure 8).                                                          
           In the present study 3 patients were reported as cases of 
recurrence of CRC, one patient with signet ring cell carcinoma & 
the other two with well-differentiated adenocarcinoma.         
Metastasis was reported in one patient. 
            Histology of tissue biopsies was shown in (Figures 9, 10, 
11, 12, 13& 14 ) as well differentiated adenocarcinoma, 
  36
moderately differentiated adenocarcinoma, poorly differentiated 
adenocarcinoma, mucinous adenocarcinoma, signet ring cell 
carcinoma & papillary carcinoma, respectively.  
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Table (1): Sex distribution and male to female incidence rate                       
ratios for cancer of the colon & rectum among the 
studied group.        
 
Male Female          
Site Frequency Percent Frequency Percent 
Incidence 
Rate Ratio 
Rectum 33 60% 22 40% 1.5:1 
Colon 23 51.1% 22 48.9% 1:1 
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Table (2): Presenting symptoms of colorectal cancer among 
the studied group.       
 
Symptoms Frequency Percent 
Rectal bleeding 76 76% 
Abdominal pain 19 19% 
Altered bowel habit 12 12% 
Constipation 5 5% 
Diarrhoea 23 23% 
Weight loss 13 13% 
Vomiting 1 1% 
Fatigability 4 4% 
Painful defecation 9 9% 
Abdominal mass 11 11% 
Others 23 23% 
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Table (3): Grading of colorectal cancer among the studied 
group.       
 
Tumor differentiation Frequency Percent 
Well differentiated 26 27.37% 
Moderately differentiated 36 37.89% 
Poorly differentiated 32 33.68% 
Undifferentiated 1 1.05% 
Total 95 100% 
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Figure(1): Age distribution of colorectal cancer among the 
studied group.  (N=100)
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Figure(2): Sex distribution of colorectal cancer 
among the studied group. (N=100)
Female
44%
Male
56%
  42
 
 
 
 
 
 
 
 
 
Figure(3): Age specific incidence rate of colorectal cancer in 
males & females among the studied group.
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Figure(5): Subsite distribution of colorectal 
cancer among the studied group. (N=100)
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Figure (6): Histological patterns (Diagnosis) of colorectal cancer 
among the studied group. (N=100)
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Fig (9): Well-differentiated adenocarcinoma.  Invasive simple 
malignant glands surrounded by desmoplasia (H&E. X10). 
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Fig (10): Moderately differentiated adenocarci-
noma. Complex infiltrating malignant glands with 
areas of solid pattern.(H&E. X10). 
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Fig. (11): Poorly differentiated adenocarcinoma. 
Solid pattern without significant gland formation (H&E. X20). 
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Fig (12): Mucinous adenocarcinoma.   Consisting of 
malignant glandular elements in extracellular 
mucin lakes.(H&E. X10).  
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Fig (13): Signet ring carcinoma. Consisting of 
signet ring cells containing intracellular 
mucin.(H&E. X20). 
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Fig (14): Papillary carcinoma  
Consists of papillations with fibrovascular cores 
and epithelial tufts.(H&E. X20).  
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DISCUSSION 
 
 
            This is a descriptive retrospective study about CRC in 
Sudanese patients. It was carried in the period from January 2001 
to December 2004 & includes analysis of 100 cases.   
            The epidemiology of CRC has generated more interest 
recently due to new developments in genetics and molecular 
biology of this disease. The epidemiological pattern of the disease 
varies markedly between different population groups.(96) 
           The incidence of CRC has been of great interest to many 
workers particularly in African countries, were it has been reported 
to be relatively lower than in affluent societies.(7) The World Health 
Organization(WHO) forsees the overall global situation in respect 
to CRC will be worsen.(97) During the latter years in Sudan, there 
has been a significant increase not in the total number of cancers 
but also in the cancers of the large bowel.  The socioeconomic 
changes & urbanization, which take place in Sudanese society, 
entails characterization of this cancer, which is usually linked with 
economic development. 
           In Sudan as in most developing countries, there is at 
present no reliable statistical information on absolute cancer rates. 
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As our study was limited to registered data, many difficulties were 
faced in the interpretation of the results due to undetailed history, 
histopathological diagnosis & staging of the neoplasia. As a result 
of this, our study indicated that 74% were adenocarcinoma, in 
contrast to what accepted globally that, up to 98% of CRC are 
adenocarcinoma.(16) But in general the adenocarcinoma 
represented the majority (74%) of histopathological patterns of 
CRC in this study. Other histological types seen were signet ring 
carcinoma (7%), mucinous carcinoma (13%), papillary carcinoma 
(5%) & anaplastic carcinoma (1%). No cases of anaplastic or 
papillary carcinoma were reported in reviewed local studies. 
          In this study, our results are in accordance with the literature 
regarding the occurrence of high number of cases among 
males.(16,17) It was reported that CRC has a different sex 
distribution with nearly similar incidence between the males & 
females for colon cancer and a male preponderance for rectal 
cancer.(16) This is almost the same trend encountered with males 
to females incidence rate ratio for colon & for rectal cancer in this 
study. The high incidence of rectal cancer in males can also be 
explained by the fact that Sudanese females are very shy & very 
reluctant to specific examination as proctoscopy & sigmoidoscopy.  
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          Another important features highlighted by the study is the 
resemblance of our data with those from developing countries 
regarding the early age of onset of CRC & left side subsite 
preponderance,(98,99,100,101,102) compared to late age at diagnosis & 
right side cancer (proximal shift) in the developed countries.(103) 
Early age of incidence is a characteristic in developing countries. 
Under age of 40, there are more than one-third of cases in 
Egypt,(99) 21.4% in Saudi Arabia,(104) & 17% in Philippine,(102) 
compared to 3.6% in USA,(105) & 7.6% in Canada,(106) In our study 
only four patients were reported to have history of U.C. & all the 
four were young patients. This in addition to another young patient 
with positive family history of CRC. But these can not fully explain 
the early incidence of CRC. 
       In the present study, left side preponderance is clear as 77% 
of cases in the rectum, rectosigmoid junction, & sigmoid colon. In 
addition to 2% of cases in the descending colon. The proximal shift 
in developed countries is not clearly discussed in the literature, 
although some relate it to possibly more effective screening in the 
right side, or to real reduction In rectal cancer incidence.(103) 
       In this study the incidence rate for males increases with age, 
at first rapidly till the age group 20-<40 years, then slowly until 
reaching a peak at the age group 60 years & over. While females 
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had two peaks, one at the age group 20-<40 years & the other at 
the age group 60 years & over. Both of the females’ peaks were 
higher than those of males. This compared to a study done in 
Yemen in which both sexes showed their peak incidence at the 
age group 55-<65 years, but the peak for males was higher than 
that for females.(107)   
       Regarding the residency, most of the patients (74%) were 
from the central region of Sudan, of them about two thirds were 
from Khartoum. No one was found to be from the South. These 
may be due to the following factors: 
(1)  Most of the Sudanese are clustered in the big towns. 
(2) There is discrepancy between the number of doctors, 
particularly specialists, & the populations they serve. 
(3)  Because of difficulty in the transportation, many patients, 
especially from the rural regions, are unlikely to reach 
hospitals. 
(4)  Finally, the shortage in medical services & the war situations in 
Southern Sudan prevented southern patients from reaching 
hospital.      
          The racial history of the patients was not found in the 
records, so was not analyzed.  
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          The majority of patients present with symptoms of bleeding 
per rectum (76%), diarrhoea (23%), abdominal pain (19%), weight 
loss (13%) & altered bowel habits (12%) in various combinations. 
While acute obstruction & perforation were not features, as this 
hospital deals with elective operations only. The duration of 
symptoms varies from one month to one year in the majority of 
patients, with a median of 6 month of the total duration. In fact 
>50% of patients had symptoms < 6-month duration & this can be 
explained by the fact that: most of the patients in this study 
presented with rectal bleeding, which is the symptom that make 
patient to seek medical advice. 
          The majority of patients in this study present with tumors at 
early stages of differentiation (moderately & well differentiated), 
while few number present with poorly & undifferentiated tumors. 
This may be due to increase awareness of cancer & improved 
facilities for diagnosis. 
          In this study anaplastic carcinoma show the highest 
incidence in males, while in females adenocarcinoma show the 
highest incidence. Signet ring carcinoma was predominant in the 
younger age group compared to other age groups, while 
anaplastic carcinoma & adenocarcinoma were predominant in the 
age group 60 years & over. 
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CONCLUSION 
 
• Only 5 histological variants were identified in this study i.e. 
adenocarcinoma, mucinous carcinoma, signet ring carcinoma, 
papillary carcinoma, & anaplastic carcinoma. 
• CRC is not an uncommon disease in this part of the world as 
used to be considered previously. 
• Despite limitation in the background history, detailed 
histopathological diagnosis & staging, the study indicated that 
developing countries characteristics as the presence of relatively 
high proportion of early onset tumor & left-sided preponderance 
are clear.  
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RECOMMENDATIONS 
 
• Further in-depth studies should be carried out to address the 
possible community-related risk factors of this cancer & to know 
the causes of early-onset CRC. 
• Education of the public about the nature of the disease & about 
the warning signs of CRC. And to achieve this; efficient use of 
press & audiovisual media is necessary. 
• Execution of screening programs for early detection & better 
outcome. 
• Detailed histopathological diagnosis & staging, & improvement 
of cancer reporting & registering activities. 
• The request form should be designed to contain detailed history 
about the patient. 
• Construction of a bowel clinic for the lower gastrointestinal 
problems.   
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ﻡﻴﺤﺭﻟﺍ  ﻥﻤﺤﺭﻟﺍ  ﷲﺍ  ﻡﺴﺒ 
University of Khartoum 
The Graduate College 
Medical & Health Studies Board 
Questionnaire  
Colorectal cancer 
 
• Lab. No.:.................... 
1- Name:........................................................ 
 2- Age (in years):........................................................ 
 3- Sex:         1- Male              2- Female   
 4- Tribe: ..……………………………………..…..........   
 5- Residence: ……………………………………….. 
6- Clinical remarks:   1- Rectal bleeding.  2- Diarrhoea.    3- Constipation 
                                     4- Fatigability          5- Abdominal pain  6- Weight loss 
                                     7- Others: ……………………………………………….  
7- Diagnosed by:       
    a. Endoscopy and biopsy:     1- Yes        2- No     
                                    Type: ……………………… …………………………. 
    a. Surgical:                              1- Yes        2- No     
                                  Type: ……………………… ………………………. 
9- Histopathology:  Gross: …………………………………………….. 
Microscopy: …………………………………………  
Diagnosis: ……………………………………………  
Stage and grade: ……………………………………  
10. Other investigations:   
- C.B.C: ………………………………….…………………  
- Barium enema: ……………………………………………  
- U/S: ………………………………………………..………  
- C. T scan: …………………………………………………  
 
 
